IP Verse

Anticancer Compositions

Patent No. EP3226841 (titled "Anticancer Compositions") was filed by Aragon Pharmaceuticals on Dec 3, 2015. The application was issued on Oct 9, 2024.

Patent Summary

Pharmaceutical formulations of ARN-509 for treating androgen receptor-related diseases, particularly prostate cancer, comprising a solid dispersion of ARN-509 and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in a weight ratio of 1:1 to 1:5. The solid dispersion can be prepared by melt-extruding or spray-drying ARN-509 and HPMCAS, and can be formulated into particles or tablets for oral administration.

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BRAND MURRAY FULLERJul 9, 2025BRAND MURRAY FULLER
EIPJul 9, 2025EIP
HEXALJul 9, 2025MAIWALD
TEVA PHARMACEUTICALSJul 8, 2025D YOUNG
HAMM & WITTKOPPJul 7, 2025HAMM & WITTKOPP
ZENTIVA KSJul 7, 2025REDDIE & GROSE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3226841

ARAGON PHARMACEUTICALS
Application Number
EP15817641A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Sep 6, 2024
Publication Date
Oct 9, 2024
External Links
Slate, Register , Google Patents